Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the success of commercialization. Recently, Viva Biotech's portfolio companies have new updates. Keep reading for more details.
Full-Life Technologies Announces USD $47.3 million Series B Financing, and Broke Ground for GMP Manufacturing Facility in Belgium
Shanghai, Gembloux, Belgium, and Heidelberg, Germany - Jan. 4, 2024 - Full-Life Technologies ("Full-Life"), invested by Viva BioInnovator (VBI), is a fully integrated global radiotherapeutics company. They announced the completion of $63.3 million financing, comprised of $47.3 million in Series B equity financing and $16 million in loan facilities. The financing will advance development of the Company's radiopharmaceutical pipeline and manufacturing capabilities, as well as optimize its proprietary discovery platform, UniRDCTM. With completion of such financing, Full-Life has secured more than $110 million funding since its inception in August 2021, including equity financing, loan facilities, and government subsidies.
On Dec. 8th, 2023, Full-Life aslo announced the construction of its new Good Manufacturing Practices (GMP) compliant manufacturing facility in Gembloux, Belgium, for radiopharmaceuticals. This strategic investment aims to advance Full-Life’s end-to-end solution by enhancing its radiopharmaceutical production capabilities at a key logistical hub to ensure the timely supply and delivery to patients worldwide.
VivaVision Receives Funding from the "Enterprise Support Scheme" of Hong Kong's Innovation and Technology Commission and is Named on Hurun Global Cheetah Index 2023
Vivavision's subsidiary, which is a company focused on differentiated and globally novel ophthalmic innovative drugs and was incubated and invested in by Viva BioInnovator (VBI), recently announced that its innovative retinal drug VVN481 has successfully obtained funding from Hong Kong's Innovation and Technology Commission’s “Enterprise Support Scheme” (ESS—Hong Kong-Israel R&D Cooperation Programme). This funding will be used to advance the preclinical R&D work of this pipeline to accelerate its progress towards clinical stage. In addition, VivaVision was also named on Hurun Global Cheetah Index 2023.
Technoderma Medicines Completes Phase I Dose Escalation Clinical Trial of TDM-180935 for Eczema/Dermatitis Indication
On Dec. 4th, 2023, Technoderma Medicines, Inc. (“Technoderma Medicines”), a clinical-stage biopharmaceutical company invested and incubated by Viva BioInnovator (VBI), announced that it has completed a Phase I clinical trial (NCT05525468) of TDM-180935 topical ointment for the treatment of atopic dermatitis/eczema. The results all met expectations.
Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate
VANCOUVER, Wash., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), invested by Viva BioInnovator (VBI), is a leader in generative AI antibody discovery.They announced a collaboration with AstraZeneca, a global biopharmaceutical company, to deliver an AI-designed antibody against an oncology target. This collaboration combines Absci's Integrated Drug Creation™ platform with AstraZeneca's expertise in oncology with the goal of accelerating the discovery of a potential new cancer treatment candidate. It is reported that the agreement includes an upfront commitment, R&D funding and milestone payments, etc., with a total with a total amount up to $247 million.
About Full-Life Technologies
Full-Life Technologies Limited (“Full-Life”) is a fully integrated global radiotherapeutics company with operations in Belgium, Germany, and China. We seek to own the entire value chain for radiopharmaceutical research & development, production & commercialization in order to deliver clinical impact for patients. The company plans to attack core issues affecting radiopharmaceuticals today through innovative research that targets the treatments of tomorrow. We are comprised of a team of fast-moving entrepreneurs and scientists with a demonstrated track record in the life sciences, as well as radioisotope research and clinical development.
About VivaVision Biotech
VivaVision is a clinical stage pharmaceutical company focused on best-in-class and first-in-class therapies for ocular diseases. VivaVision's current pipeline includes VVN001 for treating dry eye syndrome, VVN539 for the treatment for Glaucoma or Ocular Hypertension, and VVN461 for the treatment of non-infectious ocular inflammation of Uveitis. VivaVision is also engaged in discovery and development of novel therapies for the treatment of other anterior and posterior eye diseases. For more info, visit www.vivavisionbio.com.
About Technoderma Medicines
Technoderma Medicines, Inc. is a privately held clinical stage biopharmaceutical company. The Company was originally located in Jiaxing Xiuzhou Biomedicine Guoqian Park, China, and recently relocated to Chengdu Biomed Town, Chengdu, Sichuan Province, China. Its current core programs focus on development of innovative therapies for Androgenetic Alopecia, Atopic Dermatitis, Psoriasis and Lupus Erythematosus. Its "first-in-class" small molecule thyromimetic drug candidate TDM-105795 for Androgenetic Alopecia is currently in Phase 2a clinical testing. Technoderma's novel JAK1/TYK2 inhibitor TDM-180935 for Atopic Dermatitis is now in Phase 1 clinical testing. The pipeline targets dermatologic indications.
Absci is a generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to learn, the AI to create, and the wet lab to validate, Absci can screen billions of cells per week, allowing it to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Absci’s vision is to deliver breakthrough therapeutics at the click of a button, for everyone. Absci's headquarters is in Vancouver, WA, its AI Research Lab is in New York City, and its Innovation Center is in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.